Your session is about to expire
← Back to Search
OKN-007 + Temozolomide for Recurrent Brain Cancer
Study Summary
This trial is testing a new drug, OKN-007, to see if it is effective, safe, and has the desired pharmacological properties when combined with the standard chemotherapy drug, temozolomide, in treating patients with recurrent glioblastoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My scans show clear tumor growth, and I have at least one tumor that can be measured.My glioblastoma was confirmed and I've had specific treatments but not bevacizumab.I have not taken chemotherapy drugs within the forbidden time before joining the study.I do not expect to need treatment for another cancer within 6 months, except for skin cancer.I haven't taken any experimental drugs in the last 28 days.I am using or will start using the Optune device for my tumor.I have recovered from side effects of previous treatments.I am 18 years old or older.My kidney, liver, and bone marrow are functioning well.My medical records show my cancer's MGMT status or I can provide a tissue sample for testing.I can take care of myself and am up and about more than half of my waking hours.I recently had surgery to remove a recurring tumor, confirmed by an MRI.I have had up to two treatments for glioblastoma, but not bevacizumab.I have received or will receive bevacizumab for my brain tumor.I stopped taking TMZ early because of side effects.
- Group 1: All patients
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have similar tests been conducted previously?
"Schering-Plough first sponsored a study on OKN-007 way back in 2002. Since then, there have been 218 active studies conducted in 36 countries and 947 cities."
How many places are doing this research?
"Right now, potential patients can go to 11 different sites to enroll in this clinical trial. The locations of these centres are: Providence, Birmingham, Detroit and other places. Depending on where you live, it might be best to choose the closest location to cut down on travel time if you decide to participate."
Are people still able to join this clinical trial?
"According to clinicaltrials.gov, this trial is no longer recruiting patients for participation. This study was originally posted on June 12th 2020 and was last edited on October 25th 2022. Although this particular trial has closed recruitment, there are 1885 other studies that are still actively recruiting patients."
Can you please summarize the risks associated with OKN-007?
"OKN-007 falls into the Phase 2 category, meaning that while there is data supporting its safety, there are no studies yet affirming its efficacy. Consequently, Power rates it as a 2 in terms of safety."
What other research studies have there been on OKN-007?
"Currently, 218 active clinical trials are investigating the efficacy of OKN-007. Among these studies, 25 are in Phase 3. Additionally, while the majority of these trials are located in Seoul and Songpa, there are a total of 4,820 locations conducting these investigations."
How many people are eligible for this clinical trial?
"This study isn't enrolling patients at the moment. The listing for this clinical trial was first posted on June 12th, 2020 and was last edited on October 25th, 2022. For those seeking other trials, 1667 brain-related studies and 218 OKN-007 related studies are currently looking for participants."
What is the standard protocol for OKN-007?
"nitrosourea treatment is most commonly treated with OKN-007. However, OKN-007 has also been shown to be effective in treating refractory neuroblastoma, mycosis fungoides, and advanced directives."
Share this study with friends
Copy Link
Messenger